Data gathered: July 12
AI Stock Analysis - Moderna (MRNA)
Analysis generated June 16, 2025. Powered by Chat GPT.
Moderna, Inc. is a biotechnology company that has revolutionized the healthcare industry with its innovative mRNA technology. The company gained worldwide recognition and financial success during the COVID-19 pandemic with its highly effective vaccine. Moderna specializes in the development and commercialization of mRNA-based vaccines and therapies. Despite its groundbreaking success, like any other company in the volatile biotechnology sector, Moderna faces unique market dynamics and financial risks.
Stock Alerts - Moderna (MRNA)
 |
Moderna | July 8 Price is up by 7.3% in the last 24h. |
|
Moderna | July 1 Price is up by 7.4% in the last 24h. |
|
Moderna | June 17 Employee Rating is down by 2.9% over the last month. |
|
Moderna | June 17 Over the past few months, there has been an downward trend in the business outlook. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Moderna
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 146 | Sign up | Sign up | Sign up |
| Sentiment | 76 | Sign up | Sign up | Sign up |
| Webpage traffic | 162,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 85 | Sign up | Sign up | Sign up |
| Patents | 228 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 107 | Sign up | Sign up | Sign up |
| Facebook Followers | 26,065 | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 284 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 109,909 | Sign up | Sign up | Sign up |
| Twitter Followers | 144,602 | Sign up | Sign up | Sign up |
| Twitter Mentions | 138 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 11,900 | Sign up | Sign up | Sign up |
| News Mentions | 4 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $117,000 | Sign up | Sign up | Sign up |
| Business Outlook | 35 | Sign up | Sign up | Sign up |
| Linkedin Employees | 6,833 | Sign up | Sign up | Sign up |
About Moderna
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
| Price | $33.64 |
| Target Price | Sign up |
| Volume | 6,920,000 |
| Market Cap | $13.3B |
| Year Range | $23.65 - $54.63 |
| Dividend Yield | 0% |
| PE Ratio | 24.73 |
| Analyst Rating | 16% buy |
| Industry | Drug Manufacturers |
In the news
 |
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key InsightsJuly 11 - Yahoo |
|
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To KnowJuly 11 - Yahoo |
 |
FDA approves Moderna COVID-19 vaccine for high-risk childrenJuly 11 - Techtarget.com |
|
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsJuly 11 - Yahoo |
|
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025July 10 - Yahoo |
Moderna : to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025July 10 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 107M | 90M | 17M | -971M | -924M | -2.520 |
| Q4 '24 | 956M | 739M | 217M | -1.12B | -1.12B | -2.910 |
| Q3 '24 | 1.86B | 514M | 1.34B | 13M | 79M | 0.030 |
| Q2 '24 | 241M | 156M | 85M | -1.28B | -1.23B | -3.330 |
| Q1 '24 | 167M | 132M | 35M | -1.18B | -1.12B | -3.070 |
Insider Transactions View All
| Hussain Abbas filed to sell 580 shares at $28. June 12 '25 |
| SAGAN PAUL filed to buy 312,027 shares at $31.8. March 4 '25 |
| Bancel Stephane filed to buy 9,210,686 shares at $31.5. March 4 '25 |
| Bancel Stephane filed to buy 9,153,193 shares at $31. March 4 '25 |
| Klinger Shannon Thyme filed to sell 20,446 shares at $44.7. December 10 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$156.9 0% | 36 |
 |
Eli Lilly and CompanyLLY |
$793.01 0% | 61 |
 |
PfizerPFE |
$25.65 0% | 54 |
 |
AstrazenecaAZN |
$71.13 0% | 58 |
 |
AbbVieABBV |
$192.45 0% | 46 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Mar 28, 25 | Buy | $1K - $15K |
| Julie Johnson |
Feb 13, 25 | Sell | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
Read more about Moderna (MRNA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Moderna?
The Market Cap of Moderna is $13.3B.
What is Moderna's PE Ratio?
As of today, Moderna's PE (Price to Earnings) ratio is 24.73.
What is the current stock price of Moderna?
Currently, the price of one share of Moderna stock is $33.64.
How can I analyze the MRNA stock price chart for investment decisions?
The MRNA stock price chart above provides a comprehensive visual representation of Moderna's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Moderna shares. Our platform offers an up-to-date MRNA stock price chart, along with technical data analysis and alternative data insights.
Does MRNA offer dividends to its shareholders?
As of our latest update, Moderna (MRNA) does not offer dividends to its shareholders. Investors interested in Moderna should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Moderna?
Some of the similar stocks of Moderna are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.